Abstract:Although highly active antiretroviral therapy (HAART) has changed infection with human immunodeficiency virus (HIV) from a diagnosis with imminent mortality to a chronic illness, HIV positive patients who do not develop acquired immunodeficiency syndrome (AIDs) still suffer from a high rate of cardiac dysfunction and fibrosis. Regardless of viral load and CD count, HIV-associated cardiomyopathy (HIVAC) still causes a high rate of mortality and morbidity amongst HIV patients. While this is a well characterized clinical phenomena, the molecular mechanism of HIVAC is not well understood. In this review, we consolidate, analyze, and discuss current research on the intersection between autophagy and HIVAC. Multiple studies have linked dysregulation in various regulators and functional components of autophagy to HIV infection regardless of mode of viral entry, i.e., coronary, cardiac chamber, or pericardial space. HIV proteins, including negative regulatory factor (Nef), glycoprotein 120 (gp120), and transactivator (Tat), have been shown to interact with type II microtubule-associated protein-1 β light chain (LC3-II), Rubiquitin, SQSTM1/p62, Rab7, autophagy-specific gene 7 (ATG7), and lysosomal-associated membrane protein 1 (LAMP1), all molecules critical to normal autophagy. HIV infection can also induce dysregulation of mitochondrial bioenergetics by altering production and equilibrium of adenosine triphosphate (ATP), mitochondrial reactive oxygen species (ROS), and calcium. These changes alter mitochondrial mass and morphology, which normally trigger autophagy to clear away dysfunctional organelles. However, with HIV infection also triggering autophagy dysfunction, these abnormal mitochondria accumulate and contribute to myocardial dysfunction. Likewise, use of HAART, azidothymidine and Abacavir, have been shown to induce cardiac dysfunction and fibrosis by inducing abnormal autophagy during antiretroviral therapy. Conversely, studies have shown that increasing autophagy can reduce the accumulation of dysfunctional mitochondria and restore cardiomyocyte function. Interestingly, Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has also been shown to reduce HIV-induced cytotoxicity by regulating autophagy-related proteins, making it a non-antiviral agent with the potential to treat HIVAC. In this review, we synthesize these findings to provide a better understanding of the role autophagy plays in HIVAC and discuss the potential pharmacologic targets unveiled by this research.

Emerging roles of senolytics/senomorphics in HIV-related co-morbidities

Accelerated Aging process in Patients Living with HIV: Role of Mitochondrial Dysfunction.

Current Scenario and Strategies to Tackle Cardiovascular Disease Risk in HIV Geriatrics

Cardiac and Renal Comorbidities in Aging People Living With HIV

The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging

The Role of Glutathione in the Management of Cell-Mediated Immune Responses in Individuals with HIV

Management of HIV in the older adults: Clinical and public health challenge

Analysis of drug-drug interactions in patients with HIV and metabolic syndrome

Management of human immunodeficiency virus infection in advanced age

Therapeutic opportunities for senolysis in cardiovascular disease

The role of cellular senescence in diabetes mellitus and osteoporosis: molecular pathways and potential interventions

HIV antiretroviral therapy drugs induce premature senescence and altered physiology in HUVECs

Negative Lifestyle Factors Specific to Aging Persons Living with HIV and Multimorbidity

Potential Clinical Implications of Senotherapies for Cardiovascular Disease

Targeting cellular senescence: A promising approach in respiratory diseases

HIV and comorbidities - the importance of gut inflammation and the kynurenine pathway

Emerging nanotechnology approaches for HIV/AIDS treatment and prevention

The ageing immune system as a potential target of senolytics

Senolytic drugs: from discovery to translation

The role of autophagy in the progression of HIV infected cardiomyopathy

Targeting senescent cells in aging and COVID-19: from cellular mechanisms to therapeutic opportunities